SOLV · 10-Q · 2026Q2 · Full report

Products and Technology

Solventum Corp · 2026-08-05 · Importance 26 · Surprise 24

MedSurg growth was driven by I.V. site management products, including Tegaderm CHG, and by negative pressure wound therapy in Advanced Wound Care. Dental Solutions growth came from restorative and prevention solutions and orthodontics solutions, with new products launched in the prior year contributing to performance. Health Information Systems growth reflected continued adoption of Solventum™ 360 Encompass™ and Performance Management Solutions. Clinician productivity solutions declined because of changing market conditions.

Key facts

• PSU performance is measured over a three-year period ending December 31, 2028. source
• Goodwill balance as of June 30, 2026: $5,626 million, down from $5,704 million at December 31, 2025. source
• Total intangible assets — net as of June 30, 2026: $2,408 million, down from $2,592 million at December 31, 2025. source
• Solventum is organized into three reportable business segments: MedSurg, Dental Solutions, and Health Information Systems. source